In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
SCOTUS places ‘tombstone’ on Chevron doctrine, upending operation of federal agencies
By
Kimberly Bonvissuto
Jul 01, 2024
A Supreme Court decision handed down Friday morning could transform the way federal agencies operate, providing the basis for senior living operators and other companies to challenge agency decisions.